MedPage Today March 20, 2025
— Initial analysis suggests Inflation Reduction Act provision will pay off
Key Takeaways
- Medicare was authorized to negotiate prices it will pay for Part D drugs.
- Enbrel, the original version of etanercept, was among the first 10 drugs to be subject to negotiations.
- The negotiated price for Enbrel is close to the statutory maximum, for reasons that are not clear because of substantial secrecy in the process.
Negotiations to set prices Medicare will pay for the original branded version of etanercept, Enbrel, should bring the government some genuine savings, and may indirectly make it more affordable for everyone, a new analysis indicated.
Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act...
Today's Sponsors
Today's Sponsor